Arun Kumar*, Sandhya Badoni, Aarti Sati
Department of Pharmaceutical Sciences, Shri Guru Ram Rai Institute of Technology and Sciences, Patel Nagar, Dehradun, Uttarakhand, India
*Address for Corresponding Author
Arun Kumar
Department of Pharmaceutical Sciences, Shri Guru Ram Rai Institute of Technology and Sciences, Patel Nagar, Dehradun, Uttarakhand, India
Abstract
Background: Endothelial cells concerned in modulating vascular tone and structure. Endothelial plays an important role in homeostasis of the body and its dysfunction is correlated with numerous pathophysiology circumstances like diabetes, atherosclerosis. Patients with diabetes at all times show an impairment of endothelium-dependent vasodilation. Hyperglycaemia is the key aspect which develops the endothelial dysfunction in diabetes mellitus. Objective: The present study was aimed to investigate the activity of Dapagliflozin to reduce the risk of endothelial dysfunction associated with diabetes. Materials and Methods: Type 2 diabetes was induced by a single intraperitoneal injection of STZ (65mg/kg) + NAD (235mg/kg).After the administration of Streptozotocin (STZ) the animal showed marked hyperglycemia. Metformin and Captopril used as the standard drugs and the test drug Dapagliflozin administered for 28 days after the induction of endothelial dysfunction. Results: After 28 days of treatment with Dapagliflozin (10,20mg/kg) showed significant reduction in glucose level, glutathione level and improvement in lipid profiles. The treatment showed significant increase in body weight as compared to diabetic control and diabetes + endothelial dysfunction group. Conclusion: In the present study investigation, the activity of Dapagliflozin not only reduces the diabetes but also found to reduce the risk of endothelial dysfunction associated with diabetes.
Keywords: Diabetes, endothelial dysfunction, atherosclerosis, reactive oxygen species, nitric oxide, Streptozotocin
